摘要目前,已发现循环微小RNA( microRNA,miR)在体液中可稳定存在,其表达谱和表达量的变化与肿瘤等多种疾病相关；因此,循环miR很有希望成为相关疾病下一代新的生物标志物.然而,至今在有关循环miR的临床研究中,始终存在使用标本来源不一致、检测方法多样、数据分析缺乏标准化等多种缺陷,因而导致研究数据重复性较差、结论不统一,很难真正应用于临床诊疗工作中.对这些问题的解决,今后我们需要进一步规范标本选择、改进检测试剂和检测方法、对检测结果的数据分析和判读等进行标准化,以最终实现临床实验室能够快速、简便、低成本的检测循环miR,辅助开展疾病的临床诊断和治疗.

abstractsmicroRNA(miR) in body fluids shows good stability and the change in its expression profile and level is associated with cancer and other diseases.Thus,circulating miR has been proposed to be an useful biomarker in diagnosis of the onset,prognosis and risk of diseases.Although great discoveries have been obtained on all aspects of miR,there are some shortcomings existing in the present studies,such as inconsistent specimens,diverse detection methods,lack of standardization on data analysis and other defects,resulting in poor reproducibility of data and inconsistent clinical conclusion,that make circulating miR difficult to be used in clinical laboratory testing.So lots of work is needed for us to implement,such as standardizing sample selection,improving detection reagents and methods,and normalizing test results before we can ultimately establish a fast,easy,low-cost detection of circulating miR in the clinical laboratory.